137 related articles for article (PubMed ID: 27511884)
41. Bacteroides fragilis-derived lipopolysaccharide produces cell activation and lethal toxicity via toll-like receptor 4.
Mancuso G; Midiri A; Biondo C; Beninati C; Gambuzza M; Macrì D; Bellantoni A; Weintraub A; Espevik T; Teti G
Infect Immun; 2005 Sep; 73(9):5620-7. PubMed ID: 16113279
[TBL] [Abstract][Full Text] [Related]
42. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer.
Griesmann H; Drexel C; Milosevic N; Sipos B; Rosendahl J; Gress TM; Michl P
Gut; 2017 Jul; 66(7):1278-1285. PubMed ID: 27013602
[TBL] [Abstract][Full Text] [Related]
43. CD36 Differently Regulates Macrophage Responses to Smooth and Rough Lipopolysaccharide.
Biedroń R; Peruń A; Józefowski S
PLoS One; 2016; 11(4):e0153558. PubMed ID: 27073833
[TBL] [Abstract][Full Text] [Related]
44. Interferon-gamma and bacterial lipopolysaccharide act synergistically on human neutrophils enhancing interleukin-8, interleukin-1beta, tumor necrosis factor-alpha, and interleukin-12 p70 secretion and phagocytosis via upregulation of toll-like receptor 4.
Pearl-Yafe M; Fabian I; Halperin D; Flatau E; Werber S; Shalit I
Shock; 2007 Mar; 27(3):226-31. PubMed ID: 17304101
[TBL] [Abstract][Full Text] [Related]
45. Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity.
Baer C; Squadrito ML; Laoui D; Thompson D; Hansen SK; Kiialainen A; Hoves S; Ries CH; Ooi CH; De Palma M
Nat Cell Biol; 2016 Jul; 18(7):790-802. PubMed ID: 27295554
[TBL] [Abstract][Full Text] [Related]
46. 4-Methoxylonchocarpin attenuates inflammation by inhibiting lipopolysaccharide binding to Toll-like receptor of macrophages and M1 macrophage polarization.
Jang HM; Kang GD; Van Le TK; Lim SM; Jang DS; Kim DH
Int Immunopharmacol; 2017 Apr; 45():90-97. PubMed ID: 28189973
[TBL] [Abstract][Full Text] [Related]
47. Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto D; Wallet SM; Hughes SJ
Pharmacol Ther; 2016 Oct; 166():9-29. PubMed ID: 27343757
[TBL] [Abstract][Full Text] [Related]
48. Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.
Bastea LI; Liou GY; Pandey V; Fleming AK; von Roemeling CA; Doeppler H; Li Z; Qiu Y; Edenfield B; Copland JA; Tun HW; Storz P
Cancer Res; 2019 Apr; 79(7):1535-1548. PubMed ID: 30696657
[TBL] [Abstract][Full Text] [Related]
49. Macrophages in pancreatic cancer: An immunometabolic perspective.
Yang J; Li Y; Sun Z; Zhan H
Cancer Lett; 2021 Feb; 498():188-200. PubMed ID: 33122097
[TBL] [Abstract][Full Text] [Related]
50. Targeted molecular imaging of TLR4 in hepatocellular carcinoma using zwitterionic near-infrared fluorophores.
Ji Y; Wang Z; Bao K; Park GK; Kang H; Hu S; McDonald E; Kim MS; Kashiwagi S; Choi HS
Quant Imaging Med Surg; 2019 Sep; 9(9):1548-1555. PubMed ID: 31667140
[TBL] [Abstract][Full Text] [Related]
51. Targeting macrophages to treat pancreatic cancer.
Philip PA
Lancet Oncol; 2016 May; 17(5):552-3. PubMed ID: 27055730
[No Abstract] [Full Text] [Related]
52. Discussion.
J Am Coll Surg; 2019 Jul; 229(1):27-29. PubMed ID: 31248522
[No Abstract] [Full Text] [Related]
53. Pancreatic Cancer: a rare tumor with a devastating health toll.
Fleshman J
Rare Tumors; 2010 Sep; 2(3):e52. PubMed ID: 21139967
[No Abstract] [Full Text] [Related]
54. Upregulated Matrisomal Proteins and Extracellular Matrix Mechanosignaling Underlie Obesity-Associated Promotion of Pancreatic Ductal Adenocarcinoma.
Waldron RT; Lugea A; Chang HH; Su HY; Quiros C; Lewis MS; Che M; Ramanujan VK; Rozengurt E; Eibl G; Pandol SJ
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672675
[TBL] [Abstract][Full Text] [Related]
55. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.
Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
[TBL] [Abstract][Full Text] [Related]
56. Role of CD14 in human disease.
Sharygin D; Koniaris LG; Wells C; Zimmers TA; Hamidi T
Immunology; 2023 Jul; 169(3):260-270. PubMed ID: 36840585
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro.
Deveci Ozkan A; Guney Eskiler G; Kaleli S; Sahin E
Mol Biol Rep; 2022 Feb; 49(2):1261-1271. PubMed ID: 34826050
[TBL] [Abstract][Full Text] [Related]
58. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
59. Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development.
Bellotti R; Speth C; Adolph TE; Lass-Flörl C; Effenberger M; Öfner D; Maglione M
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298645
[TBL] [Abstract][Full Text] [Related]
60. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming.
Yang S; Liu Q; Liao Q
Front Cell Dev Biol; 2020; 8():607209. PubMed ID: 33505964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
